Fortis Healthcare Q1FY26 Concall Decoded: EBITDA +43%, Net Profit +46%, ARPOB Hits ₹2.65 Cr

1. Opening Hook

Hospitals usually bleed cash, but this quarter Fortis looked like it was billing by the second. Occupancy rose, ARPOB shot up 10%, and EBITDA margins expanded nearly 400 bps. Throw in a 228-bed Jalandhar buy, a 700-bed Gleneagles O&M deal, and a ₹1,869 Cr net debt bill — and you get Fortis looking like it wants to be both doctor and landlord.

Stay with me — because robotic surgeries up 75% and oncology growing 28% means Fortis isn’t just selling beds, it’s selling high-margin hope.

2. At a Glance

Revenue ₹2,167 Cr (+16.6%) – Patients aren’t cutting medical bills, recession or not.
Hospitals ₹1,838 Cr (+18.6%) – 85% of topline, and 100% of management’s bragging rights.
Diagnostics ₹329 Cr (+6.3%) – Agilus finally acting less like a sidekick.
EBITDA ₹491 Cr (22.6% margin, +400 bps) – That’s some surgical efficiency.
PAT ₹254 Cr (+46.2%) – Even after higher debt costs, net profit swelling.
Net Debt ₹1,869 Cr (0.92x EBITDA) – Borrowed to buy Agilus stake + Fortis brand.
ARPOB ₹2.65 Cr (+10%) – Oncology + robots = patients paying Ferrari prices.

3. Management’s Key Commentary

Quote: “We added 228 beds via Jalandhar acquisition, can scale to 450.”
(Translation: Bought land, selling ICU dreams on EMI.)

Quote: “Signed O&M deal for 700 Gleneagles beds at 3% topline fee.”
(Translation: We don’t own them, but we do send the bill 😏)

Quote: “EBITDA margins expanded to 22.6%.”
(Translation: Case mix + robots = ka-ching.)

Quote: “Oncology grew 28%, robotic surgeries up 75%.”
(Translation: High-tech scalpel > regular scalpel.)

Quote: “Diagnostics EBITDA margin 23% vs 16% LY.”
(Translation: Agilus finally doing less ‘agila’, more stable work.)

Quote: “900 beds to be added this year; 50% operational in FY26.”
(Translation: Expansion with brownfield speed, not greenfield pain.)

Quote: “Net debt rose to fund Agilus buy + Fortis brand rights.”
(Translation: Borrowed to buy our own name back 🙃)

4. Numbers Decoded

Metric	Q1 FY26	YoY Change	One-Line Analysis
Revenue	₹2,167 Cr	+16.6%	Healthy topline, hospital biz driving it.
Hospital Revenue	₹1,838 Cr	+18.6%	Bed occupancy + ARPOB surge = double boost.
Diagnostics Rev	₹329 Cr	+6.3%	Still lagging peers, but margins rescued story.
EBITDA	₹491 Cr	+43.2%	Margins jumped 400 bps, high case mix impact.
EBITDA Margin	22.6%	+420 bps	Best quarter in years, sustaining guidance key.
PAT	₹254 Cr	+46.2%	Clean profit growth, no one-offs.
Net Debt	₹1,869 Cr	0.92x	Up sharply, but still